Windtree Therapeutics, Inc.

Windtree ended Q1 with $29.4 million in cash and cash equivalents and said that cash is sufficient to fund operations through Q1 2017, including expected completion of the AEROSURF Phase IIb trial. It reported accounts payable and accrued expenses of $14.6 million and long-term debt with Deerfield of $25 million, payable in two $12.5 million installments in February 2018 and February 2019. Q1 operating loss was $13.9 million versus $11.2 million in Q1 2015, driven mainly by higher R&D expense for AEROSURF clinical trials; net loss was $13.9 million, or $1.70 per share, versus $12.2 million, or $1.96 per share, a year ago. Net cash burn was $9.3 million, including $1.5 million of 2015 employee incentive compensation payments, and management forecast Q2 net cash burn of approximately $8.5 million.

Craig Fraser framed the quarter as one of “solid execution” and emphasized that the company is staying focused on timely Phase II completion, international site expansion, and preserving cash. He highlighted that observational data and prior IIa results are changing the company’s view of where the clinical and commercial opportunity may be, especially in older preterm infants and earlier in the treatment pathway. His tone was constructive and disciplined, with repeated emphasis on transparency, execution, and a stronger value-creation position for shareholders.

John Tattory said the company finished Q1 with $29.4 million in cash and expects that to carry it through Q1 2017, even after planned Phase IIb completion. He attributed the higher operating loss of $13.9 million to increased AEROSURF R&D spending, including patient enrollment, site initiations and manufacturing of clinic-ready delivery systems, while interest expense declined to $600,000 from $1.2 million due to the Deerfield debt restructuring. He also said the company reallocated about $2 million toward risk-mitigation activities, with just over 50% of that tied to a headcount reduction, and that this is already reflected in the cash forecast.

The main analyst question focused on whether Phase IIb would effectively be two studies by gestational age group and how results would be reported. Management said it will not be treated as separate trials; instead, the company will start with 29- to 32-week babies, then add 26- to 28-week babies once IIa data are available, and it will assess overall results as well as subgroup performance. On Phase III, management said the goal remains to complete the full 26- to 34-week range in the Phase IIb program and that this study is intended as important supportive data for registration.